Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$570.0 million.

  • Caribou Biosciences' Retained Earnings fell 3805.45% to -$570.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.0 million, marking a year-over-year decrease of 3805.45%. This contributed to the annual value of -$448.4 million for FY2024, which is 4982.04% down from last year.
  • Latest data reveals that Caribou Biosciences reported Retained Earnings of -$570.0 million as of Q3 2025, which was down 3805.45% from -$542.5 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Retained Earnings high stood at -$58.3 million for Q2 2021, and its period low was -$570.0 million during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$259.8 million (2023), whereas its average is -$282.7 million.
  • In the last 5 years, Caribou Biosciences' Retained Earnings tumbled by 21678.27% in 2021 and then crashed by 3805.45% in 2025.
  • Over the past 5 years, Caribou Biosciences' Retained Earnings (Quarter) stood at -$97.8 million in 2021, then plummeted by 101.66% to -$197.2 million in 2022, then plummeted by 51.76% to -$299.3 million in 2023, then tumbled by 49.82% to -$448.4 million in 2024, then dropped by 27.13% to -$570.0 million in 2025.
  • Its last three reported values are -$570.0 million in Q3 2025, -$542.5 million for Q2 2025, and -$488.4 million during Q1 2025.